# Global Active Pharmaceutical Ingredient (API) Market (2023-2029) --- ## Report Summary The Global Active Pharmaceutical Ingredient (API) Market worth USD 207.5 billion in 2025 is projected to reach USD 314.3 billion by 2031, growing at a CAGR of 7.12% during 2025-2031. --- ## Global API Market Table of Content Table of Content - 1. Global API Market Overview - 1.1. Market Highlights - 1.2. Global API Market Taxonomy - 2. Global API Market Ecosystem - 3. Global API Market Size (in USD Bn), 2018-2023 - 4. Global API Market Segmentation, 2023 - 4.1. Global API Market Segmentation by Business Mode (in revenue %), 2023 - 4.2. Global API Market Segmentation by Type (in revenue %), 2023 - 4.3. Regional Transition of Global API Market - 4.4. Global API Market Segmentation by Drug Type (in revenue %), 2023 - 4.5. Global API Market Segmentation by Application (in revenue %), 2023 - 5. Global API Market Competitor Analysis - 5.1. Global API Market Company Profile - 5.2. Global API Market Players Cross-Comparison, 2022 - 6. Global API Market Industry Analysis - 6.1. Growth Drivers in Global API Market - 6.2. Challenges in Global API Market - 6.3. Recent Development in Global API Market - 7. Global API Market Future Market Size (in USD Mn), 2023-2029 - 8. Global API Market Macro Indicators - 8.1. Dependency Rate 2022 - 8.2. GDP Growth Rate 2023 - 8.3. Inflation Rate 2023 - 9. Global API Market Research Methodology - 9.1. Global API Market Definitions - 9.2. Global API Market Sizing Approach - 10. Frequently Asked Questions on Global API Market --- ## Global API Market Overview Global API Market Highlights The Global API Market was valued at USD 160.4 Bn in 2018 and grew at a CAGR of 5.3% during 2018–2023. The market is further anticipated to reach USD 314.3 Bn by 2029, expanding at a projected CAGR of 7.2% during the forecast period of 2023–2029. Structurally, the market remains moderately fragmented, with the presence of several large and established players. Growth in the market is being driven by higher pharmaceutical demand following the 2020–2021 pandemic period, which accelerated research and development activity, along with the expansion of API manufacturers in selected regions benefiting from economies of scale. *The Global API Market, valued at USD 160.4 Bn in 2018, grown with a Compound Annual Growth Rate (CAGR) of 5.3% from 2018 to 2023* --- ## Taxonomy | ID | Parent ID | Label | | --- | --- | --- | | 1 | | Global Active Pharmaceuticals Ingredient Market | | 2 | 1 | Type | | 3 | 2 | Synthetic | | 4 | 2 | Natural | | 5 | 1 | By Application | | 6 | 5 | Ophthalmology | | 7 | 5 | Oncology | | 8 | 5 | Pulmonology | | 9 | 5 | Cardiology | | 10 | 5 | Neurology | | 11 | 5 | Other Applications | | 12 | 1 | Drug Type | | 13 | 12 | Generic | | 14 | 12 | Branded | | 15 | 1 | Business Mode | | 16 | 15 | Captive API | | 17 | 15 | Merchant API | | 18 | 1 | Region | | 19 | 18 | North America | | 20 | 18 | Europe | | 21 | 18 | Asia-Pacific | | 22 | 18 | Rest of the World | --- ## Global API Market Ecosystem ### Market Ecosystem **Ecosystem of Global API Market** --- ## Global API Market (in USD Mn), 2018-2023 The current Active Pharmaceutical Ingredient (API) market has grown at a CAGR of 5.3%, reaching a market size of USD 207.5 Bn in 2023. This growth has been primarily supported by the rising number of API manufacturers in the Asia-Pacific region, driven by greater ease of doing business and lower operating costs, particularly in China. The market, however, experienced a slowdown in 2020, with growth declining from 5.1% to 4.5%, mainly due to supply chain disruptions caused by nationwide restrictions imposed to contain COVID-19. At the same time, the pandemic also created excess demand for medicines, and alongside the rising prevalence of diseases, this contributed to stronger demand growth in 2020 and 2021. --- ## Global API Market Segmentation, 2023 ### Global API Market by Business Mode (in revenue %) Most Active Pharmaceutical Ingredient (API) manufacturers operate under the captive business mode, which accounted for 77% of the market in 2023, valued at USD 159.8 Bn. In comparison, the merchant API segment contributed 23% of total revenue during the same year, despite a growing trend among companies to outsource manufacturing in order to reduce costs and avoid investment in expensive equipment and sophisticated infrastructure. The growth of the merchant API market is being supported by the increasing importance of generic drugs, technological advancements in API manufacturing, and capacity expansion initiatives by pharmaceutical and biopharmaceutical companies. ### Global API Market by Type (in revenue %), 2023 Synthetic APIs accounted for 72% of the revenue share of the Active Pharmaceutical Ingredient market, valued at USD 149.9 Bn, while Natural APIs constituted the remaining 28% share, valued at USD 58.1 Bn. Synthetic APIs dominate the market due to their ease of manufacturing, affordability, and convenience, as chemical synthesis makes them easier to produce and often less expensive than natural counterparts. In addition, synthetic APIs provide greater control over the manufacturing process, enabling more consistent quality and purity, while also offering better stability and longer shelf life, which supports scalability. Although synthetic APIs remain the dominant segment, natural APIs are expected to witness faster growth, driven by increasing investments in biopharmaceuticals that are enabling the development of new molecules for diseases such as cancer. ### Regional Analysis of Global API Market (in revenue %), 2023 Asia-Pacific leads the Global Active Pharmaceutical Ingredient (API) Market with approximately 62% of total revenue share, valued at USD 128.7 Bn, followed by Europe at 22% with USD 45.7 Bn, North America at 9% with USD 18.7 Bn, and the Rest of the World accounting for the remaining 7% with USD 14.5 Bn. Although the USA dominates the demand side of the API market with over 41% share, a large portion of global supply is fulfilled by the Asia-Pacific region, particularly China and India. APAC is expected to continue dominating the global API market, as China supplies nearly 80% of the intermediates used worldwide for API manufacturing, while India remains one of the largest API manufacturing hubs, alongside South Korea. This regional dominance is primarily supported by lower production costs, driven by comparatively lower raw material, electricity, and labor costs. --- ## Global API Market Industry Analysis ### Global API Market Growth Drivers **Increasing Prevalence of Infectious, Genetic, Cardiovascular, and Other Chronic Disorder** According to the Global Burden of Cardiovascular Diseases and Risk Factors study, the estimated number of prevalent cases of ischemic heart disease (IHD) was 197 million in 2019. The Heart Disease and Stroke Statistics 2023 Update report from the American Heart Association states that chronic diseases are now the dominant contributors to the global burden of disease, and cardiovascular disease is the largest contributor to the chronic disease cluster, with 17.9 million people dying annually. **Increasing Adoption of Biologicals and Biosimilar** Biosimilar has the capacity to increase competition among manufacturers, reduce prices, and improve patient access to these medicines. And therefore, have been leveraged to ensure access to medicine to most of the people, by making it affordable. **Rising Prevalence of Cancer and Increasing Sophistication in Oncology Drug Research** Advances in technology and research have led to the development of more sophisticated oncology drugs, including targeted therapies and immunotherapies, which have improved patient outcomes. The increasing prevalence of chronic diseases such as diabetes and obesity has been linked to an increased risk of cancer. In addition to the above factors, lifestyle factors such as poor diet, lack of physical activity, and tobacco and alcohol use are major contributors to the rise in cancer incidence. The global cancer incidence rate in 2023 is estimated to be around 19.3 million new cancer excluding no melanoma skin cancer, representing a 47% rise from 2020. ### Challenges in Global API Market **Tightened Regulations** API manufacturers encounter challenges from tightened regulations, which can impact manufacturing processes and compliance requirements. For instance, stringent data integrity requirements imposed by regulatory bodies like the US FDA. **Shortages and Supply Chain Disruptions** The industry has experienced shortages and disruptions in API supply chains, compounded by booming transportation costs, disorganization, and slowdown of production line. This has been particularly evident during the pandemic, where the health crisis has highlighted structural supply difficulties, especially in the U.S., which imports nearly 70% of APIs. The slowdown in production lines has further exacerbated the challenges faced by pharmaceutical companies, impacting their ability to meet demand and maintain a stable supply of essential medicines **Reshoring and Regulatory Changes** Efforts to reshore API production and move production closer to home have been hindered by the lack of investment in manufacturing sites, high costs, and regulatory changes. Many U.S.-based pharmaceutical companies have planned to reshore and move their production closer to home to address these challenges. However, a major obstacle in their onshoring efforts is the lack of investment in manufacturing sites. This lack of investment has hindered the industry's ability to ramp up production and address the shortages and disruptions in the API supply chain. ### Recent Developments in Global API Market **Mergers and Acquisitions** Companies like WuXi STA and Asychem Inc. invested in expanding their HPAPI (High-Potency API) manufacturing capacities. Glenmark Pharmaceuticals and Nirma Limited: Glenmark Pharmaceuticals entered into a definitive agreement with Nirma Limited to divest a 75% stake in its subsidiary. Pintaluba Group and Lek Veterina: Pintaluba Group acquired Lek Veterina, a Slovenian company, in the veterinary and pharmaceutical industries. **Expansion in Research and Development** Merck: an investment of € 35 million in biosafety testing at Glasgow and Stirling sites in Scotland. Biosafety testing is a critical step in the drug development and manufacturing process to ensure that drugs are safe, efficacious, and compliant with regulatory requirements. Investment includes a new 1,200-square-meter facility in Glasgow, which will house molecular biology and sequencing services. Signed a non-binding memorandum of understanding with the Korean Ministry of Trade, Industry and Energy, and Daejeon City, Korea, for a new Asia-Pacific Bioprocessing Centre aimed at supporting the region’s healthcare ecosystem. Glen Mark: With focus on Oncology several innovations of the company are underway- GRC 54276 (HPK1 Inhibitor) is being developed as an orally administered IO-adjuvant treatment for patients with solid tumors. GRC 54276 is a novel, orally active HPK1 inhibitor that demonstrates standalone efficacy and enhances current immunotherapy efficacy. GRC 54276 is currently being evaluated in the First in Human (FIH) Phase 1 clinical study (GRC 54276-101), and others. TEVA: TEVA is conducting clinical trials to test the efficacy and safety of its investigational drugs, such as TEV-48574, for the treatment of asthma and inflammatory bowel disease. The company is also collaborating with the Celiac Disease Foundation to test TEV-53408, an investigational antibody designed to block interleukin 15 (IL-15), for the treatment of celiac disease --- ## Global API Market Company Profile | Year | Company | Description | | --- | --- | --- | | 1668 | The Merck Group | The first pharmaceutical company in the world, founded by Friedrich Jacob Merck in Germany, has transformed into a Science and Technology company. Around 83% of the company’s total revenue is generated from life sciences and healthcare, while the remaining 17% comes from electronics (2022). The Life Science business is research-driven and innovation-focused. In 2016, the company invested EUR 260 million in R&D, enabling the launch of 2,100 new innovative products, developed to meet customers’ unmet needs ranging from antibodies to water purification systems. | | 1999 | AstraZeneca plc | AstraZeneca Plc is a holding company engaged in the research, development, and manufacturing of pharmaceutical products. Its pipeline focuses on therapy areas including oncology, cardiovascular, renal, metabolism, and respiratory diseases. Founded on June 17, 1992, the company is headquartered in Cambridge, United Kingdom. AstraZeneca is a global science-led, patient-focused pharmaceutical company committed to transforming the future of healthcare by unlocking the power of science for people, society, and the planet. | | 1901 | Teva Pharmaceutical Industries Ltd. | Teva’s portfolio of around 3,600 products is among the largest in the pharmaceutical industry. Nearly 200 million people in 60 countries benefit from Teva medicines every day. Teva API supplies high-quality APIs to over 1,000 customers worldwide. Its portfolio includes more than 400 APIs manufactured across 16 advanced production facilities, employing over 5,000 highly trained professionals. Teva remains committed to environmental, health, and safety (EHS) standards to ensure sustainable production. | | 1849 | Pfizer Inc. | Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. The company was founded in 1849 by Charles Pfizer and Charles F. Erhart. Pfizer currently operates in 181 countries, delivering over 80 million doses of medicines and vaccines and reaching approximately 1.3 billion patients worldwide, equivalent to 1 out of every 6 people globally. | --- ## Global API Future Market Size ### Global API Future Market Size (in USD Mn), 2023-2029 The Global API Market is anticipated to grow at a CAGR of 7.2%, increasing in value from USD 207.5 Bn in 2023 to USD 314.3 Bn by 2029. This growth is expected to be driven by factors such as increasing global healthcare needs, stronger pandemic preparedness and response capabilities, and supportive regulatory frameworks. In addition, the forecast period is likely to witness stronger momentum in Natural or Large Molecule APIs, as major companies such as Merck, Pfizer, and Teva continue to explore treatments and cures for chronic diseases. --- ## Global API Market Macro Indicators ### Dependency Ratio, 2022 The dependency ratio is defined as the number of children and older persons per hundred persons of working age. In 2022, the ratio was at 54% and is projected to grow to around 60% by elderly population is one of the main recipients of health care, and with the increase in their numbers the demand for availing medical care, and hence the medicines would also grow. ### GDP Growth, 2023 The Outlook projects global GDP growth of 2.9% in 2023, followed by a mild slowdown to 2.7% in 2024 and a slight improvement to 3.0% in 2025. Asia is expected to continue to account for the bulk of global growth in 2024-25, as it has in 2023. Moreover taking a subset of World’ GDP, the G20 economies; Asia-Pacific is anticipated to drive the GDP growth of the world ### Inflation Rate, 2023 With the rise in Inflation in the global scenario, the cost of availing raw material, energy cost and others facilities, leads to a hike in operational cost of the companies. As most of the raw material for the manufacturing of API and henceforth medicine are imported from the APAC region to rest of the world. Therefore, an increase in inflation could have a detrimental effect on the growth of Global API Market. However, a decline in inflation would have an opposite effect. --- ## Frequently Asked Questions Find quick answers to common questions about the Global API Market **Q: What is the difference between an active ingredient and an active pharmaceutical ingredient?** A: Active ingredients are the substances in drugs that are responsible for the beneficial health effects experienced by consumers. The active ingredient in a pharmaceutical drug is called an active pharmaceutical ingredient (API). An example of an API is the acetaminophen contained in a pain relief tablet **Q: What is the CAGR of the Global API Industry during 2023-2029?** A: The Global API pharma market is anticipated to grow at a rate of 7.2% for the given time period. **Q: How do market dynamics impact the API industry?** A: Market dynamics, such as changes in healthcare policies, patent expirations, and emerging diseases, can significantly influence the demand and supply of APIs. Global economic factors and geopolitical events may also impact the industry. **Q: What is the future outlook for the API industry?** A: The future of the API industry is expected to be shaped by advancements in biotechnology, personalized medicine, and digital manufacturing technologies. There is also a growing focus on ensuring a stable and diversified supply chain.